促红素对胃癌相关性贫血的疗效与预后的影响观察
|
摘要
目的探究胃癌相关性贫血使用促红素进行治疗临床疗效以及预后情况。方法选取我院2015年4月~2016年8月收入98例胃癌相关性贫血患者作为此次研究对象,按照治疗方式不同分为观察组和对照组,各49例,对照组使用常规化疗以及常规抗贫血治疗,观察组使用常规化疗并予以促红素治疗,比较两组血液水平指标变化、临床治疗效以及不良反应发生率。结果两组治疗前后血液指标水平变化中两组治疗前差异无统计学意义(P>0.05),两组治疗后差异有统计学意义(P<0.05),两组治疗疗效比较中观察组95.9%高于对照组79.6%,差异有统计学意义(P<0.05),两组不良反应中观察组14.3%低于对照组30.6%,两组差异有统计学意义(P<0.05)。结论临床上使用促红素对于肿瘤相关性贫血治疗效果较为明显,可以使血红蛋白有效升高,减少临床上不良反应发生,可以在临床上推广使用。
Objective To investigate the clinical curative effect and prognosis of patients with gastric cancerrelated anemia. Methods In this study,98 patients with gastric cancer associated anemia in our hospital were divided into observation group(n=49) and control group(n=49).The patients in the control group were treated with conventional chemotherapy and antianemia therapy,while the patients in the observation group were treated with conventional chemotherapy and propofol.The changes of blood level,the clinical curative effect and the incidence of adverse reactions were compared between the two groups. Results There was no significant difference before and after treatment between the two groups(P > 0.05).The difference between the two groups after treatment was statistically significant(P < 0.05).The observation group was 95.9% higher than the control group(79.6%) in the comparison of therapeutic efficacy.The difference was statistically significant.The adverse reactions in the observation group were lower than that in the control group(14.3% vs 30.6%,P < 0.05),and the difference between the two groups was statistically significant(P < 0.05). Conclusion The clinical effect of the treatment of tumor-associated anemia by using propofol is obvious,which can effectively increase hemoglobin,reduce the occurrence of clinical adverse reactions,and can be popularized in clinic.
Objective To investigate the clinical curative effect and prognosis of patients with gastric cancerrelated anemia. Methods In this study,98 patients with gastric cancer associated anemia in our hospital were divided into observation group(n=49) and control group(n=49).The patients in the control group were treated with conventional chemotherapy and antianemia therapy,while the patients in the observation group were treated with conventional chemotherapy and propofol.The changes of blood level,the clinical curative effect and the incidence of adverse reactions were compared between the two groups. Results There was no significant difference before and after treatment between the two groups(P > 0.05).The difference between the two groups after treatment was statistically significant(P < 0.05).The observation group was 95.9% higher than the control group(79.6%) in the comparison of therapeutic efficacy.The difference was statistically significant.The adverse reactions in the observation group were lower than that in the control group(14.3% vs 30.6%,P < 0.05),and the difference between the two groups was statistically significant(P < 0.05). Conclusion The clinical effect of the treatment of tumor-associated anemia by using propofol is obvious,which can effectively increase hemoglobin,reduce the occurrence of clinical adverse reactions,and can be popularized in clinic.
引文
[1]杜振华,魏茜雪.重组人促红素联合蔗糖铁治疗妇科恶性肿瘤相关性贫血的疗效及不良反应观察[J].中国计划生育和妇产科,2016,8(12):21-23,32.
[2]张霞,曾泗宇,石卫民,等.重组人促红素治疗恶性肿瘤伴贫血的药效观察[J].河北医学,2015,21(9):1468-1471.
[3]周殿友,习加喜,龚倩,等.1例晚期非小细胞肺癌并发重度贫血的药学监护[J].中国药物警戒,2016,13(12):757-760.
[4]胡军建.肾康注射液联合重组人促红细胞生成素治疗慢性肾功能衰竭合并肾性贫血的疗效观察[J].现代药物与临床,2017,32(2):314-318.
[5]杨斌,张建武.酶联免疫吸附法测定肿瘤性贫血患者的血清细胞因子水平及其发病机制研究[J].中国临床药理学杂志,2017,33(12):1102-1105.
[6]梁容瑞,李伟,赵晶,等.肿瘤相关性贫血患者血清促红细胞生成素水平与重组人促红细胞生成素治疗效果的关系[J].中国老年学杂志,2015,35(22):6434-6436.
[7]薛晓弘.重组人促红细胞生成素在肿瘤相关性贫血中的临床应用[J].中国医师进修杂志,2014,37(10):30-32.
[8]崔利格,魏素菊.细胞因子在肿瘤相关性贫血中的作用机制研究进展[J].肿瘤防治研究,2014,41(9):1049-1053.
[9]曾冬香,毕延智,盛桂凤,等.rh EPO联合蔗糖铁维持治疗胃肠道肿瘤化疗相关性贫血的临床观察[J].实用肿瘤杂志,2015,30(3):275-278.
[10]蒋洁,宁亚利,李东辉,等.IGF-1对胃癌血红素氧合酶-1表达的影响[J].现代肿瘤医学,2017,25(12):1945-1948.
[11]高之峰,张建福,费素娟等.食欲素A促人胃癌SGC7901细胞凋亡[J].基础医学与临床,2014,34(1):98-103.
[12]吴付兵,王星,王康霞,等.促红细胞生成素对胃癌相关性贫血患者的疗效[J].现代肿瘤医学,2015,23(2):241-243.
[13]许敏,李红.强力霉素对胃癌细胞增殖及Notch1、MMP-9表达的影响[J].天津医药,2014,42(6):533-535.
[14]周蕾,俞岚,魏军,等.胃癌组织中H.pylori-L型感染及骨桥蛋白、基质金属蛋白酶-2的表达[J].中国老年学杂志,2014,34(2):311-313.
[15]陈彦格,郝素革,王红霞,等.EEN对老年胃癌患者全胃切除术后T细胞亚群的影响[J].河北医学,2014,20(7):1118-1120.
[2]张霞,曾泗宇,石卫民,等.重组人促红素治疗恶性肿瘤伴贫血的药效观察[J].河北医学,2015,21(9):1468-1471.
[3]周殿友,习加喜,龚倩,等.1例晚期非小细胞肺癌并发重度贫血的药学监护[J].中国药物警戒,2016,13(12):757-760.
[4]胡军建.肾康注射液联合重组人促红细胞生成素治疗慢性肾功能衰竭合并肾性贫血的疗效观察[J].现代药物与临床,2017,32(2):314-318.
[5]杨斌,张建武.酶联免疫吸附法测定肿瘤性贫血患者的血清细胞因子水平及其发病机制研究[J].中国临床药理学杂志,2017,33(12):1102-1105.
[6]梁容瑞,李伟,赵晶,等.肿瘤相关性贫血患者血清促红细胞生成素水平与重组人促红细胞生成素治疗效果的关系[J].中国老年学杂志,2015,35(22):6434-6436.
[7]薛晓弘.重组人促红细胞生成素在肿瘤相关性贫血中的临床应用[J].中国医师进修杂志,2014,37(10):30-32.
[8]崔利格,魏素菊.细胞因子在肿瘤相关性贫血中的作用机制研究进展[J].肿瘤防治研究,2014,41(9):1049-1053.
[9]曾冬香,毕延智,盛桂凤,等.rh EPO联合蔗糖铁维持治疗胃肠道肿瘤化疗相关性贫血的临床观察[J].实用肿瘤杂志,2015,30(3):275-278.
[10]蒋洁,宁亚利,李东辉,等.IGF-1对胃癌血红素氧合酶-1表达的影响[J].现代肿瘤医学,2017,25(12):1945-1948.
[11]高之峰,张建福,费素娟等.食欲素A促人胃癌SGC7901细胞凋亡[J].基础医学与临床,2014,34(1):98-103.
[12]吴付兵,王星,王康霞,等.促红细胞生成素对胃癌相关性贫血患者的疗效[J].现代肿瘤医学,2015,23(2):241-243.
[13]许敏,李红.强力霉素对胃癌细胞增殖及Notch1、MMP-9表达的影响[J].天津医药,2014,42(6):533-535.
[14]周蕾,俞岚,魏军,等.胃癌组织中H.pylori-L型感染及骨桥蛋白、基质金属蛋白酶-2的表达[J].中国老年学杂志,2014,34(2):311-313.
[15]陈彦格,郝素革,王红霞,等.EEN对老年胃癌患者全胃切除术后T细胞亚群的影响[J].河北医学,2014,20(7):1118-1120.